Procaps Group SA
NASDAQ:PROC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Petroleo Brasileiro SA Petrobras
BOVESPA:PETR4
|
BR |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (7.4), the stock would be worth $1.61 (46% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.1 | $1.1 |
0%
|
| 3-Year Average | 7.4 | $1.61 |
+46%
|
| 5-Year Average | 8.3 | $1.8 |
+64%
|
| Industry Average | 5.1 | $1.1 |
0%
|
| Country Average | 9.6 | $2.09 |
+90%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| LU |
|
Procaps Group SA
NASDAQ:PROC
|
124.1m USD | 5.1 | 2.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 53.7 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 23.7 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 22.5 | 30 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 19.5 | 15.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF | 15.7 | 20.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 10.3 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 17.5 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 10.7 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 6 |
| Median | 9.6 |
| 70th Percentile | 15.1 |
| Max | 462.4 |
Other Multiples
Procaps Group SA
Glance View
Procaps Group SA develops pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
